Showing results (1101-1110 of 4,634) with videos related to
Sort By:
Pageof 464
Anti-Cancer Drugs|August 14, 2023
Anti-cancer effectiveness of a novel ceramide analog on chemo-sensitive and chemo-resistant breast cancersTulasi Ponnapakkam, Tyjah Saulsberry, Miriam Hill-Odom, et al.Anti-Cancer Drugs|August 14, 2023
Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatmentQidong Zhou, Hao Wu, Fengze Miao, et al.Anti-Cancer Drugs|March 20, 2026
D430-2307 inhibits breast cancer cell growth by dual induction of apoptosis and G0/G1 arrest via phosphatidylinositol 3-kinase/protein kinase B signalingJingge Xu, Shuling Ni, Yi Yang, et al.Anti-Cancer Drugs|May 2, 2026
Remarkable efficacy of ivonescimab-based second-line therapy in advanced lung adenocarcinoma resistant to chemoimmunotherapy: a case reportXuan Wang, Kunning Yang, Ping YinAnti-Cancer Drugs|May 2, 2026
Temozolomide-based therapy may remodel the tumor microenvironment and enhance immunotherapy sensitivity in advanced leiomyosarcomaHuijing Tan, Zhuo Li, Jianguo Zhou, et al.Anti-Cancer Drugs|May 2, 2026
The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinomaXiaoli Ma, Yu Wei, LeiYu Cao, et al.Anti-Cancer Drugs|April 4, 2026
3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivoGennady B Lapa, Toshiyuki Tsunoda, Natalia I MoiseevaAnti-Cancer Drugs|April 24, 2026
Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature reviewZixin Chen, Lin ChenAnti-Cancer Drugs|April 22, 2026
SENP3-mediated deSUMOylation stabilizes programmed death-ligand 1 to promote immune evasion in hepatocellular carcinomaBin Zhang, Jianbo Zheng, Yingan Zhao, et al.Pageof 464